Clinical Trials Logo

Colitis, Ulcerative clinical trials

View clinical trials related to Colitis, Ulcerative.

Filter by:

NCT ID: NCT05384080 Active, not recruiting - Ulcerative Colitis Clinical Trials

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

VARIETY
Start date: August 8, 2022
Phase:
Study type: Observational

The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland. There is no treatment involved in this study, this is only an observational review of ongoing/initiating treatment data relating to Vedolizumab induction and maintenance treatment for IBD [including Ulcerative Colitis (UC) and Crohn's Disease (CD)].

NCT ID: NCT05382715 Recruiting - Colitis, Ulcerative Clinical Trials

A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis

COLIBRI
Start date: May 30, 2022
Phase:
Study type: Observational

The purpose of this study is to monitor the use, effectiveness and treatment persistence with Ozanimod (Zeposia®) as well as quality of life in participants undergoing treatment for moderate-to-severe ulcerative colitis (UC).

NCT ID: NCT05377580 Recruiting - Clinical trials for Ulcerative Colitis (UC)

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.

NCT ID: NCT05372939 Completed - Ulcerative Colitis Clinical Trials

Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

Start date: February 5, 2021
Phase: Phase 2
Study type: Interventional

Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Combination With Adalimumab in Subjects with Moderate to Severe Ulcerative Colitis.

NCT ID: NCT05370885 Recruiting - Ulcerative Colitis Clinical Trials

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Start date: May 8, 2023
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).

NCT ID: NCT05369832 Recruiting - Colitis, Ulcerative Clinical Trials

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Start date: December 16, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.

NCT ID: NCT05341401 Not yet recruiting - Clinical trials for Ulcerative Colitis Chronic

Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis

Start date: June 2022
Phase: Phase 2/Phase 3
Study type: Interventional

My study aims to directly compare the efficacy and safety of Budesonide MMX versus Prednisolone in the management of mild to moderate cases of ulcerative colitis.

NCT ID: NCT05336773 Not yet recruiting - Ulcerative Colitis Clinical Trials

Ulcerative Colitis Mayo Score With Artificial Intelligence

Start date: April 2022
Phase:
Study type: Observational

This project will use deep learning to classify colonoscopy images of different severity of ulcerative colitis, so as to assist clinicians in the accurate diagnosis of ulcerative colitis.

NCT ID: NCT05327790 Recruiting - Ulcerative Colitis Clinical Trials

LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

Start date: June 3, 2022
Phase: Phase 2
Study type: Interventional

To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.

NCT ID: NCT05321485 Recruiting - Ulcerative Colitis Clinical Trials

The Effect of MedicijnWijs on Adherence to Azathioprine Therapy in Adolescents With IBD

MEDICATION
Start date: March 16, 2022
Phase: N/A
Study type: Interventional

Medication non-adherence is an existing problem in patients with inflammatory bowel diseases (IBD). Adherence rates are especially low in children and adolescents. Good medication adherence is key in achieving lower disease activity and longer periods of remission. Previous research has shown education can increase medication adherence. MedicijnWijs is a mobile phone app containing a module concerning a 6-weeks guidance with azathioprine therapy. It provides information about IBD and azathioprine. In this multicenter before-and-after study, the aim is to assess the effect of MedicijnWijs on the adherence to azathioprine therapy in adolescents with IBD. This is done using two validated questionnaires that are translated to Dutch: the Medication Adherence Report Scale-5 (MARS-5), which tests the participants' adherence to azathioprine therapy, and the Inflammatory Bowel Disease Knowledge Inventory Device 2 (IBD-KID2), which tests the participants' knowledge about IBD. These questionnaires are filled in at the beginning of the study period and after 6 weeks of using MedicijnWijs. This way a change in both scores can be assessed. The investigators hypothesize that MedicijnWijs will help increase the adherence to azathioprine therapy in adolescents with IBD.